[go: up one dir, main page]

WO2022265577A3 - Coronavirus enzyme modulators, methods of synthesis and uses thereof - Google Patents

Coronavirus enzyme modulators, methods of synthesis and uses thereof Download PDF

Info

Publication number
WO2022265577A3
WO2022265577A3 PCT/SG2022/050408 SG2022050408W WO2022265577A3 WO 2022265577 A3 WO2022265577 A3 WO 2022265577A3 SG 2022050408 W SG2022050408 W SG 2022050408W WO 2022265577 A3 WO2022265577 A3 WO 2022265577A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthesis
methods
enzyme modulators
coronavirus
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2022/050408
Other languages
French (fr)
Other versions
WO2022265577A2 (en
Inventor
Cheng San Brian Chia
Qian Wen TAN
Subramanyam VANKADARA
Yi Yang SEE
Shuyi Pearly NG
Weijun Xu
Choon Heng LOW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of WO2022265577A2 publication Critical patent/WO2022265577A2/en
Publication of WO2022265577A3 publication Critical patent/WO2022265577A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates, in general terms, to coronavirus 3CL protease enzyme modulators, their methods of synthesis and uses thereof. In particular, the enzyme modulators can be used for inhibiting coronavirus 3CL protease and thereby prevent replication of the virus.
PCT/SG2022/050408 2021-06-15 2022-06-14 Coronavirus enzyme modulators, methods of synthesis and uses thereof Ceased WO2022265577A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10202106405S 2021-06-15
SG10202106405S 2021-06-15

Publications (2)

Publication Number Publication Date
WO2022265577A2 WO2022265577A2 (en) 2022-12-22
WO2022265577A3 true WO2022265577A3 (en) 2023-02-02

Family

ID=84527675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2022/050408 Ceased WO2022265577A2 (en) 2021-06-15 2022-06-14 Coronavirus enzyme modulators, methods of synthesis and uses thereof

Country Status (1)

Country Link
WO (1) WO2022265577A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025507472A (en) * 2022-03-01 2025-03-21 ウエストバック バイオファーマ カンパニー リミテッド Ketoamide derivatives and their use in pharmaceuticals

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029435A1 (en) * 1996-12-27 1998-07-09 Boehringer Ingelheim (Canada) Ltd. Peptidomimetic inhibitors of the human cytomegalovirus protease
US6187905B1 (en) * 1998-05-06 2001-02-13 Hoffmann-La Roche Inc. Alpha-ketoamide derivatives
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
WO2002008187A1 (en) * 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2007041775A1 (en) * 2005-10-10 2007-04-19 The University Of Queensland Cysteine protease inhibitors incorporating azide groups
US20140243341A1 (en) * 2011-09-27 2014-08-28 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
WO2018042343A2 (en) * 2016-08-30 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Compounds that inhibit 3c and 3cl proteases and methods of use thereof
WO2021207409A2 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of sars-cov-2 viral replication and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029435A1 (en) * 1996-12-27 1998-07-09 Boehringer Ingelheim (Canada) Ltd. Peptidomimetic inhibitors of the human cytomegalovirus protease
US6187905B1 (en) * 1998-05-06 2001-02-13 Hoffmann-La Roche Inc. Alpha-ketoamide derivatives
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
WO2002008187A1 (en) * 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2007041775A1 (en) * 2005-10-10 2007-04-19 The University Of Queensland Cysteine protease inhibitors incorporating azide groups
US20140243341A1 (en) * 2011-09-27 2014-08-28 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
WO2018042343A2 (en) * 2016-08-30 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Compounds that inhibit 3c and 3cl proteases and methods of use thereof
WO2021207409A2 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of sars-cov-2 viral replication and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUNMEI WANG: "Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study", 21 February 2020 (2020-02-21), XP055729381, Retrieved from the Internet <URL:https://chemrxiv.org/articles/Fast_Identification_of_Possible_Drug_Treatment_of_Coronavirus_Disease_-19_COVID-19_Through_Computational_Drug_Repurposing_Study/11875446/1> [retrieved on 20200910], DOI: 10.26434/chemrxiv.11875446.v1 *
KHER, S.S. ET AL.: "Substrate derived peptidic a-ketoamides as inhibitors of the malarial protease PfSUB1", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 18, 7 August 2014 (2014-08-07), pages 4486 - 4489, XP029053324, [retrieved on 20221208], DOI: 10.1016/J.BMCL. 2014.07.08 6 *

Also Published As

Publication number Publication date
WO2022265577A2 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
PH12023550161A1 (en) Pharmaceutical composition and use thereof
WO2022155530A8 (en) Variant strain-based coronavirus vaccines
WO2021219091A3 (en) Quinoxalinone derivative as irreversible inhibitor of kras g12c mutant protein
WO2020106642A8 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
MX2021001376A (en) Carboxamides as ubiquitin-specific protease inhibitors.
WO2019014395A8 (en) Generation of water-soluble cannabinoid compounds in yeast and plant cell suspension cultures and compositions of matter
TW200719892A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2022217123A3 (en) Combination therapies with cbl-b inhibitor compounds
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP4309732A3 (en) Modulators of pcsk9 expression
WO2024039901A3 (en) Cdk2 degraders and uses thereof
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2022266456A3 (en) Proteases for beer haze reduction
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2022265577A3 (en) Coronavirus enzyme modulators, methods of synthesis and uses thereof
WO2022269346A3 (en) Compositions and methods of modulating xanthine dehydrogenase
WO2022184854A3 (en) Formulations of ace2 fc fusion proteins
BR112022002942A2 (en) Enzyme composition
EP4470538A3 (en) Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
MX2022002121A (en) Production of cannabinoids.
WO2023069514A9 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
WO2020102630A8 (en) Modulators of irf5 expression
WO2023064513A3 (en) Trem compositions and methods of use
WO2019204494A3 (en) Date palm medium compositions and methods

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22825440

Country of ref document: EP

Kind code of ref document: A2